Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan

Takahiko Saida; Kazumasa Yokoyama; Ryusuke Sato; Haruki Makioka; Yukihiko Iizuka; Masakazu Hase; Yan Ling; Shinichi Torii

doi:10.1007/s40120-017-0084-6

Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan

Neurol Ther. 2017 Dec;6(2):197-211. doi: 10.1007/s40120-017-0084-6. Epub 2017 Nov 8.

Authors

Takahiko Saida¹, Kazumasa Yokoyama², Ryusuke Sato³, Haruki Makioka³, Yukihiko Iizuka³, Masakazu Hase³, Yan Ling³, Shinichi Torii³

Affiliations

¹ Kansai Multiple Sclerosis Center, Kyoto Min-iren Central Hospital, Kyoto, Japan. saida_takahiko@maia.eonet.ne.jp.
² Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
³ Biogen Japan Ltd., Tokyo, Japan.

Abstract

Introduction: Natalizumab, a humanized anti-α4 integrin monoclonal antibody, received marketing approval in Japan in 2014 for the treatment of multiple sclerosis (MS). Because the previous large-scale clinical trials of natalizumab were mainly conducted in Europe and North American countries, and data in patients with MS from Japan were limited, we conducted an all-case post-marketing surveillance of natalizumab-treated MS patients from Japan to investigate the safety and effectiveness of natalizumab in a real-world clinical setting in Japan. Here, we report the results of an interim analysis.

Methods: During the observation period of 2 years, all patients who were treated with natalizumab subsequent to its approval in Japan were followed. The effectiveness of natalizumab was assessed by examining the changes in expanded disability status scale (EDSS) score and annualized relapse rate (ARR) from baseline. Safety was assessed by analyzing the incidence of adverse drug reactions (ADRs).

Results: The safety analysis included 106 patients (mean age 39.3 years; women 62.3%) whose data were collected until the data lock point (February 7, 2016). The effectiveness analysis included 75 patients. The majority of patients had relapsing-remitting MS (93/106 patients; 87.7%). The mean length of treatment exposure in the present study was 6.6 months. During the 2-year observation period, no significant change in the EDSS was observed, while the ARR decreased significantly from baseline (72.9% reduction, p = 0.001). ADRs and serious ADRs were observed in 11.3% and 3.8% of patients, respectively; however, no new safety concerns were detected. No patient had progressive multifocal leukoencephalopathy (PML) during the present study period.

Conclusion: The safety and effectiveness of natalizumab were confirmed in Japanese patients with MS in clinical practice. Nevertheless, potential risks including PML require continuous, careful observation.

Funding: Biogen Japan Ltd (Tokyo, Japan).

Keywords: Japan; Multiple sclerosis; Natalizumab; Post-marketing surveillance.